Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis.Scientific reports · 2024
   Pooled it
2. Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study.Inflammopharmacology · 2024
   Trial
3. Exploring Risk and Protective Factors in Parkinson's Disease.Cells · 2025
   Review
4. Research progress of platelets in neurodegenerative diseases.Frontiers in aging neuroscience · 2025
   Review
5. Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.PloS one · 2024
   Observational
6. COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics.Neurotoxicity research · 2022
   Review
7. Molecular mechanisms defining penetrance ofMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2022
   Article
8. Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease.International journal of molecular sciences · 2022
   Review
9. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism.Frontiers in neuroscience · 2022
   Review
10. Therapeutic Strategies for Immune Transformation in Parkinson's Disease.Journal of Parkinson's disease · 2022
    Review
11. Evidence of Inflammation in Parkinson's Disease and Its Contribution to Synucleinopathy.Journal of movement disorders · 2022
    Article

Corrections and comments

• Comment on
  Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.